A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19
Banaser et al.
, A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19
, International Journal of Medicine in Developing Countries, doi:10.24911/IJMDC.51-1640383699 (meta analysis)
Meta analysis of 8 studies showing significantly lower mortality and mechanical ventilation with low dose aspirin.
Currently there are 64 aspirin studies
and meta analysis shows:
risk of death, 49.0% lower, RR 0.51, p < 0.001.
risk of mechanical ventilation, 30.0% lower, RR 0.70, p = 0.006.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Banaser et al., 24 Dec 2021, peer-reviewed, 5 authors.
Abstract: Manal Banaser et al, 2022;6(3):526–534.
International Journal of Medicine in Developing Countries
A systematic review and meta-analysis
on efficacy of low dose aspirin on the
management of COVID-19
Manal Banaser1* , Mutaman Jarrar2,3, Ayed Alqahtani4,
Abdulelah Banaser5, Waleed Albaker6
COVID-19 pandemic has increased thrombotic risk by 35%. This pandemic led to millions of deaths due to various comorbidities and organ failure. Repurposing aspirin usage to manage COVID-19 hospitalized patients is a
logical approach for preventing cardiovascular disease and comorbidities that increase mortality risk. However,
several earlier investigations found inconsistent outcomes. This study aims to assess primary and secondary
effects in COVID-19 patients with or without aspirin. We performed a multi-database electronic search including Cochrane, Embase, Scopus, and PubMed from date of inception to November 2021 using search terms:
(“Coronavirus Disease 2019” OR “COVID-19” OR “SARS-CoV-2” OR “2019-nCoV”) AND (“Acetylsalicylic acid”
OR “acetylsalicylate” OR “aspirin” OR “antiplatelet”) AND (“mortality” OR “severe” OR “severity”). Eight retrospective studies met the study criteria comprising 7,171 aspirin users and 8,327 non-aspirin users in COVID19. Aspirin administration significantly reduces mortality risk (RR: 0.51, 95% CI: 0.46-0.57, I2 = 85.05, p-value
<0.001, τ2 = 0.028, Z-value: -11.44, p-value <0.001). Aspirin used in COVID-19 patients demonstrated reduced
bleeding risk (RR: 0.80, 95 CI%: 0.34-1.9) and reduced risk for the necessity of mechanical ventilation (RR: 0.70;
95% CI: 0.54-0.90, I2 = 0%, p-value: 0.41, τ2 = 0%) when compared with COVID-19 patients without aspirin use.
The present review found administration of a low dose of aspirin in COVID-19 patients significantly reduced
Keywords: Low dose aspirin, mortality, COVID-19, thrombosis, antiplatelet drug.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.